Cargando…
GA101 (a Novel Anti-CD20 Monoclonal Antibody)-Induced Lichenoid Eruption
INTRODUCTION: Obinutuzumab (GA101) is a novel anti-CD20 monoclonal antibody that has been shown to be effective for the treatment of non-Hodgkin’s lymphoma, and is currently being evaluated in phase 3 clinical trials. The side-effect profile of the drug is not yet well established. CASE REPORT: The...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Healthcare Communications
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3510425/ https://www.ncbi.nlm.nih.gov/pubmed/23205326 http://dx.doi.org/10.1007/s13555-012-0003-9 |